What is Zacks Research’s Estimate for ESPR FY2027 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Investment analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a note issued to investors on Tuesday, March 25th. Zacks Research analyst K. Das expects that the biopharmaceutical company will post earnings of $0.06 per share for the year. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

ESPR has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday, March 20th. Needham & Company LLC restated a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. JMP Securities reiterated a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price target on the stock. Finally, The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $6.75.

Esperion Therapeutics Price Performance

ESPR stock opened at $1.63 on Thursday. Esperion Therapeutics has a 1 year low of $1.47 and a 1 year high of $3.94. The firm has a market capitalization of $322.49 million, a P/E ratio of -2.55 and a beta of 1.04. The business’s 50-day moving average is $1.80 and its two-hundred day moving average is $2.07.

Hedge Funds Weigh In On Esperion Therapeutics

Hedge funds have recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Esperion Therapeutics by 71.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after purchasing an additional 295,378 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Esperion Therapeutics in the third quarter valued at about $94,000. BNP Paribas Financial Markets increased its holdings in shares of Esperion Therapeutics by 152.7% in the third quarter. BNP Paribas Financial Markets now owns 123,333 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 74,522 shares during the period. MetLife Investment Management LLC increased its stake in Esperion Therapeutics by 47.1% in the 3rd quarter. MetLife Investment Management LLC now owns 71,050 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 22,734 shares during the period. Finally, Wasatch Advisors LP lifted its stake in shares of Esperion Therapeutics by 38.4% in the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after acquiring an additional 6,483,070 shares during the period. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.